慢性肾功能衰竭患者联合血液透析与血液灌流治疗的效果和安全性评价

Effect and Safety Evaluation of Combined Hemodialysis and Hemoperfusion in Patients with Chronic Renal Failure

目的分析血液透析与血液灌流联合治疗对慢性肾功能衰竭(CRF)患者的临床疗效以及安全性,为相关疾病治疗提供指导意见。方法2019年7月至2020年7月选择安顺市第一人民医院收治的CRF患者102例为研究对象,采取电脑抽检法分为参照组(n=51例)与试验组(n=51例)。对其治疗前后炎性指标、肾功能、血液净化情况、不良反应等发生率进行统计分析。结果试验组不良反应发生率〔5.9%(3/51)〕低于参照组〔21.6%(11/51)〕(χ^(2)=5.229,P=0.021)。试验组治疗后肿瘤坏死因子α(TNF-α)、C反应蛋白(CRP)、白介素6(IL-6)、血尿氮(BUN)、尿肌酐(Cr)、β_(2)微球蛋白(β_(2)-MG)、同型半胱氨酸(Hcy)、甲状旁腺素(PTH)水平均低于参照组(P<0.05),肌酐清除率(Ccr)水平高于参照组(P<0.05)。结论联合治疗手段可有效改善CRF患者临床整体治疗效果,其肾功能与炎性反应均可有效缓解,且临床不良反应发生率较低,血液净化效果良好,整体治疗效果明显,安全性较高。

Objective To analyze the clinical efficacy and safety of combined hemodialysis and hemoperfusion therapy in patients with chronic renal failure,so as to provide guidance for the treatment of related diseases.Methods 102 patients with CRF treated in Anshun first people’s hospital were selected as the research object from July 2019 to July 2020.They were divided into reference group(n=51)and experimental group(n=51)by computer sampling method.The incidence of inflammatory indexes,renal function,blood purification and adverse reactions before and after treatment were statistically analyzed.Results The incidence of adverse reactions in the test group〔5.9%(3/51)〕was lower than that in the reference group〔21.6%(11/51)〕(χ^(2)=5.229,P=0.021).After treatment in the test group,tumor necrosis factorα(TNF-α),C-reactive protein(CRP),interleukin 6(IL-6),blood urine nitrogen(BUN),urine creatinine(Cr),β_(2)-microglobulin(β_(2)-MG),homocysteine(Hcy),and parathyroid hormone(PTH)levels are lower than the reference group.Conclusion Combined treatment can effectively improve the overall clinical treatment effect of chronic renal failure patients,the renal function and inflammatory reaction can be effectively alleviated,and the incidence of clinical adverse reactions is low,blood purification effect is good,the overall treatment effect is significant,high safety.